Email this article 
Post a Comment Community-aquired pneumonia in asthmatic children with different duration of inhaled corticosteroid therapy
- Authors: Bulatova E.M.1, Nesterenko Z.V.1
-
Affiliations:
- St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
- Issue: Vol 10, No 2 (2019)
- Pages: 7-12
- Section: Articles
- URL: https://journal-vniispk.ru/pediatr/article/view/13506
- DOI: https://doi.org/10.17816/PED1027-12
- ID: 13506
Cite item
Abstract
Background. The continuing increase of the prevalence of asthma in the world, the lack of the expected therapeutic effect of current programs, make this phenomenon to be studied. One of the main causes of asthma exacerbation and worsening of the prognosis in the children’s population are infectious diseases that occur in connection with steroid therapy used in the asthma treatment.
Aim: to study the relationship of steroid therapy in asthmatic children with the occurrence of community-acquired pneumonia, that changes asthma symptoms in them.
Materials and methods. 39 children aged 3-18 years old with atopic asthma who received corticosteroid therapy, were examined. All patients were divided into 4 groups: Group 1 – patients received inhaled corticosteroids for 2 years; Group 2 – for 3-5 years; Group 3 – for more than 5 years; Group 4 – patients with newly diagnosed asthma and a short course of corticosteroid therapy in the remission.
Results. The frequency of community-acquired pneumonia was analyzed in all groups. Strong positive correlation between the duration of use of moderate and moderate/high dose inhaled corticosteroid therapy in asthmatic children for more than 2 years and the occurrence of community-acquired pneumonia with development of complications (pulmonary hypertension, pulmonary fibrosis, pulmonary bullae, bronchiectasis) in 48.7% them was revealed.
Conclusions. Strong positive correlation between the duration of moderate and moderate/high dose inhaled corticosteroid therapy in asthmatic children for more than 2 years and the occurrence of community-acquired pneumonia in them was revealed, that necessitates the antibiotics to be included in the medication therapy of asthma.
Full Text
##article.viewOnOriginalSite##About the authors
Elena M. Bulatova
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: bulatova2008@gmail.com
MD, PhD, Dr Med Sci, Professor. Department of Propaedeutics of Children’s Diseases
Russian Federation, Saint PetersburgZoia V. Nesterenko
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: zovas@mail.ru
MD, PhD, Dr Med Sci, Professor. Department of Propaedeutics of Children’s Diseases
Russian Federation, Saint PetersburgReferences
- Аверьянов А.В. Хламидийная и микоплазменная инфекция при патологии нижних дыхательных путей // Лечебное дело. – 2009. – № 4. – С. 52–62. [Aver’yanov AV. Infection with Chlamydia and Mycoplasma in the Pathology of the Lower Airways. Lechebnoe delo. 2009;(4):52-62. (In Russ.)]
- Власов П.В., Кармазановский Г.Г., Шейх Ж.В., Вилявин В.Ю. Кисты и кистоподобные образования в легких // Медицинская визуализация. – 2005. – № 1. – С. 82–94. [Vlasov PV, Karmazanovskiy GG, Sheykh ZhV, Vilyavin VY. Cysts and Cystic Like Lungs Lesions. Medical visualization. 2005;(1):82-94. (In Russ.)]
- Российское респираторное общество. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». – 4-е изд. – М., 2012. [Rossiyskoe respiratornoe obshchestvo. Natsional’naya programma «Bronkhial’naya astma u detey. Strategiya lecheniya i profilaktika’. 4th ed. Moscow; 2012. (In Russ.)]
- Королева Е.Г. Роль микоплазменной инфекции в формировании и течении рецидивирующих и хронических заболеваний органов дыхания у детей: Автореф. дис. … канд. мед. наук. – СПб., 2003. [Koroleva EG. Rol’ mikoplazmennoy infektsii v formirovaniii i techenii retsidiviruyushchikh i khronicheskikh zabolevaniy organov dykhaniya u detey. [dissertation] Saint Petersburg; 2003. (In Russ.)]
- Прозоровский С.В., Раковская И.В., Вульфович Ю.В. Медицинская микоплазмология. – М.: Медицина, 1995. [Prozorovskiy SV, Rakovskaya IV, Vul’fovich YV. Meditsinskaya mikoplazmologiya. Moscow: Meditsina; 1995. (In Russ.)]
- Самсыгина Г.А. Микоплазмоз респираторного тракта у детей и подростков // Педиатрия. Приложение к журналу Consilium Medicum. – 2009. – № 3. – С. 78–81. [Samsygina GA. Mikoplazmoz respiratornogo trakta u detey i podrostkov. Pediatriya. Prilozhenie k zhurnalu Consilium Medicum. 2009;(3):78-81. (In Russ.)]
- Спичак Т.В., Катосова Л.К. Роль хламидийной инфекции при бронхиальной астме у детей // Современная педиатрия. – 2009. – № 6. – С. 59–63. [Spichak TV, Katosova LK. Role of chlamydial infection at bronchial asthma of children. Sovremennaia pediatriia. 2009;(6):59-63. (In Russ.)]
- Царев С.В., Хаитов М.Р. Роль респираторных вирусов при бронхиальной астме // РМЖ. – 2009. – Т. 17. – № 2. – С. 136–139. [Tsarev SV, Khaitov MR. Rol’ respiratornykh virusov pri bronkhial’noy astme. RMZh. 2009;17(2):136-139. (In Russ.)]
- Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163(1):29-43. https://doi.org/10.1111/j.1476-5381.2010.01199.x.
- Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384(9944):691-702. https://doi.org/10.1016/S 0140-6736(14)61136-3.
- EAACI. Global Atlas of Asthma. EAACI; 2013. 179 p.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA; 2018.
- Kraft M, Adler KB, Ingram JL, et al. Mycoplasma pneumoniae induces airway epithelial cell expression of MUC 5AC in asthma. Eur Respir J. 2008;31(1):43-46. https://doi.org/10.1183/09031936.00103307.
- Tablan OC, Reyes MP. Chronic interstitial pulmonary fibrosis following mycoplasma pneumoniae pneumonia. Am J Med. 1985;79(2):268-270. https://doi.org/10.1016/0002-9343(85)90021-x.
- Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis. 1990;141(2 Pt 2): S 89-96.
Supplementary files
